Product concentration
A limited commercial portfolio means setbacks in one product can disproportionately affect revenue.
- Scope
- TAVALISSE and REZLIDHIA
- Materiality
- high
Rigel Pharmaceuticals, Inc
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer. Its business centers on developing, commercializing, and licensing small-molecule medicines, including TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for relapsed or refractory AML, with commercial activity in the United States and partnered markets outside the U.S.
43,5 %
93,3 %
124,7 %
+64,1 %
2.42
2.30
| % | |
|---|---|
| Commercial hematology products | 70% Approved medicines sold directly or through partners for blood disorders and leukemia. |
| Licensed product collaborations | 25% Partnered commercialization, royalties, milestones, and drug supply tied to out-licensed assets. |
| Government and research-related revenue | 5% Contract revenue tied to government-supported development or research programs. |
Rigel sells primarily to hematologists and hematologist-oncologists in the U.S. who treat chronic adult ITP and AML...
- U.S. hematologists and hematologist-oncologistsprimary
Prescribe TAVALISSE and REZLIDHIA for patients with chronic ITP or AML.
- Specialty pharmacy and wholesale channel partnersprimary
Distribute commercial product to patients and support access and fulfillment.
- Pharmaceutical licensees and collaboration partnerssecondary
Buy drug supply, pay royalties, and fund milestones under global agreements.
- Government and research counterpartiessecondary
Provide contract funding for selected development or preparedness programs.
Rigel is headquartered in the United States and generates its direct commercial sales primarily in the U.S...
- •U.S. is the core commercial market for direct product sales
- •Europe and the UK are served through partnered commercialization
- •Japan, Korea, Canada, and Israel are key ex-U.S. markets for TAVALISSE
- •Partner agreements create international revenue without direct sales infrastructure
- •Geography affects reimbursement, regulatory access, and partner economics
Rigel’s strategy is to commercialize its approved hematology products while extending their reach through licensing and...
01
Defend and expand commercial uptake of TAVALISSEshort-term
The product is a core revenue driver and depends on specialist prescribing and access.
02
Build REZLIDHIA as a second commercial assetmedium-term
A second approved product diversifies disease exposure and revenue sources.
03
Monetize global rights through partnershipsmedium-term
Licensing and supply agreements extend reach without requiring full direct infrastructure.
Rigel depends on a small number of products and disease areas, so demand shortfalls, competitive therapies, or generic...
Generic and competitive pressure
Specialty pharmaceuticals face branded and generic competition that can compress demand and pricing.
- Scope
- TAVALISSE in chronic ITP
- Materiality
- high
Reimbursement and access pressure
Net sales depend on payer coverage, rebates, chargebacks, and patient assistance economics.
- Scope
- U.S. specialty pharmacy channel
- Materiality
- high
Supply chain and third-party dependence
The company relies on outside manufacturers, distributors, and logistics providers to deliver product.
- Scope
- Commercial product supply and clinical materials
- Materiality
- medium
Partner and licensing execution
International revenue depends on counterparties meeting commercialization, supply, and milestone obligations.
- Scope
- Grifols, Kissei, Medison, other collaborators
- Materiality
- medium
Variable consideration in product sales
Affects reported revenue and gross-to-net realization
Collaboration revenue recognition
Can create lumpy quarterly revenue
Deferred revenue from partner agreements
Impacts timing of reported revenue
Valuation allowance on deferred tax assets
Can materially affect tax expense and equity
RIGEL PHARMACEUTICALS INC
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
MADRIGAL PHARMACEUTICALS, INC.
MDGL · Pharmaceutical Preparations
Madrigal Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on developing and selling therapies for metabolic dysfunction-associated steatohepatitis (MASH).
INSULET CORP
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Scilex Holding Co
SCLX · Biological Products, (No Diagnostic Substances)
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products.
REGENXBIO Inc.
RGNX · Biological Products, (No Diagnostic Substances)
: 29/04/2026